CN105769875A - Preparation method of compound olanzapine fluoxetine hydrochloride capsule - Google Patents
Preparation method of compound olanzapine fluoxetine hydrochloride capsule Download PDFInfo
- Publication number
- CN105769875A CN105769875A CN201410823058.6A CN201410823058A CN105769875A CN 105769875 A CN105769875 A CN 105769875A CN 201410823058 A CN201410823058 A CN 201410823058A CN 105769875 A CN105769875 A CN 105769875A
- Authority
- CN
- China
- Prior art keywords
- olanzapine
- fluoxetine hydrochloride
- preparation
- pregelatinized starch
- recipe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005017 olanzapine Drugs 0.000 title claims abstract description 50
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title claims abstract description 49
- 229960000389 fluoxetine hydrochloride Drugs 0.000 title claims abstract description 43
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 title claims abstract description 42
- 150000001875 compounds Chemical class 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000002775 capsule Substances 0.000 title claims abstract description 22
- 229920000881 Modified starch Polymers 0.000 claims abstract description 24
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 238000005303 weighing Methods 0.000 claims abstract 3
- 238000012216 screening Methods 0.000 claims description 2
- 239000011812 mixed powder Substances 0.000 abstract description 7
- NEXXMCBZLDDQNK-UHFFFAOYSA-N 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine hydrochloride Chemical compound Cl.CNCCC(Oc1ccc(cc1)C(F)(F)F)c1ccccc1.CN1CCN(CC1)C1=Nc2ccccc2Nc2sc(C)cc12 NEXXMCBZLDDQNK-UHFFFAOYSA-N 0.000 abstract description 6
- 238000002156 mixing Methods 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 12
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 6
- 229960002464 fluoxetine Drugs 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 5
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 230000036506 anxiety Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000017194 Affective disease Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical group C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- -1 olanzapine fluoxetine Hydrochloride compound Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 229940034173 symbyax Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a preparation method of a compound olanzapine fluoxetine hydrochloride capsule. The method consists of: weighing a formulated amount of olanzapine, fluoxetine hydrochloride and pregelatinized starch and performing blending to obtain a mixture, sieving the mixture by a sieve of more than 60 meshes, then conducting mixing by a mixer to prepare an intermediate, taking the mixed powder and detecting the content of olanzapine and fluoxetine hydrochloride, and when the content is accord with the intermediate standard, performing capsule filling. The preparation method of the compound olanzapine fluoxetine hydrochloride capsule provided by the invention realizes preparation of the compound olanzapine fluoxetine hydrochloride capsule, and the solubility of the active ingredients olanzapine and fluoxetine hydrochloride can be significantly increased, thus being conducive to giving play to the efficacy.
Description
Technical field
The preparation method that the present invention relates to a kind of pharmaceutical composition, the preparation method particularly relating to a kind of compound recipe olanzapine fluoxetine hydrochloride capsules.
Background technology
Olanzapine is a kind of atypical antipsychotic, has the multiple antagonism of serotonin, norepinephrine and dopamine.Abroad in Recent Years reports that serious symptom, psychotic disease, refractory depression, depressive anxiety syndrome and bipolar affective disorder, obsession are all had good efficacy by it, especially controls depressive anxiety syndrome rapid-action.
Fluoxetine Hydrochloride is a kind of selective serotonin reuptake inhibitor (SSRI), it can absorb 5-hydroxy tryptamine by inhibitory neuron effectively from synaptic space, increasing this neurotransmitter being available for actual utilization in gap, thus improving affective state, treating depr essive disorder.
It is a recommendable treatment way that small-dose olanzapine merges fluoxetine for treatment major depressive disorder patient, not only rapid-action, overcome that the onset of fluoxetine own is slow and the shortcoming of the benzene phenodiazine easy addiction of azole antianxiety drug, and greatly reduce the expulsion rate in Fluoxetine in Treatment, and sleep and anxiety somatization can be improved rapidly, significantly improving the curative effect of antidepressant and anxiety, compliance is good, and clinic is promoted.
It is SYMBYAX that compound recipe olanzapine fluoxetine hydrochloride capsules former grinds the former name of an article of consulting and deliberating, and is researched and developed by Lilly Co., Eli., and antipsychotic drug olanzapine and antidepressant fluoxetine combined therapy are difficult to the paralepsy of the adult's I type bipolar disorder cured；In in December, 2003 in U.S.'s approval listing, subsequently in Argentina, Mexico and Chile's listing.At present domestic have no import listing, also have no the information of declaring.
Chinese invention patent application 201310139272.5 provides pharmaceutical composition of a kind of bortezomib and preparation method thereof, which employs the technical scheme that bortezomib, the tert-butyl alcohol, sodium chloride and excipient are 1: 0.5: 1～5: 5～20 with mass ratio, the dissolution velocity in water of the lyophilized formulations of gained was at about 20 seconds, relevant content of material is also far below comparison medicament, and stability significantly improves.
But still do not have the medicinal tert-butyl alcohol to provide because of domestic, also without the medicinal standard of the tert-butyl alcohol, more lack its clinical safety data, declare this kind medicine difficulty with this to CFDA also big.Prepare lyophilized injectable powder with the tert-butyl alcohol and be also easy to residual in the formulation, it is also possible to there is clinical drug safety hidden danger.For this, some technical staff have explored and have attempted.
Summary of the invention
The preparation method that it is an object of the present invention to provide a kind of compound recipe olanzapine fluoxetine hydrochloride capsules, to produce olanzapine fluoxetine Hydrochloride compound preparation.
Further object is that the preparation method that a kind of compound recipe olanzapine fluoxetine hydrochloride capsules is provided, to improve the dissolution of compound preparation, be beneficial to the performance of drug effect.
The compound recipe olanzapine fluoxetine hydrochloride capsules that the present invention relates to, including olanzapine and fluoxetine Hydrochloride isoreactivity composition, pregelatinized Starch is major auxiliary burden, substantially has 3 kinds of specifications, is respectively as follows: 3mg/25mg, 6mg/25mg and 12mg/25mg in olanzapine/fluoxetine.Along with going deep into disease research, and the situation of clinical application, its recipe quantity also can change, but must not as the restriction to technical solution of the present invention.
The preparation method of a kind of compound recipe olanzapine fluoxetine hydrochloride capsules provided by the invention, comprises the steps:
Weigh recipe quantity olanzapine, fluoxetine Hydrochloride and pregelatinized Starch and carry out blended mixture, mixture is sieved more than 60 orders, then through mixer mix (as: 20 minutes), prepare into intermediate (i.e. compound recipe olanzapine fluoxetine Hydrochloride), after taking mixed powder detection olanzapine and fluoxetine Hydrochloride content, carry out capsule filling.
The preparation method of another kind of compound recipe olanzapine fluoxetine hydrochloride capsules provided by the invention, comprises the steps:
Weigh recipe quantity olanzapine to mix with the pregelatinized Starch of part recipe quantity, mix with the fluoxetine Hydrochloride of recipe quantity again, the pregelatinized Starch being eventually adding remaining recipe quantity mixes, then the screening more than 60 orders, then through mixer mix (as: 20 minutes), prepare into intermediate (i.e. compound recipe olanzapine fluoxetine Hydrochloride), take mixed powder detection olanzapine and fluoxetine Hydrochloride content, after meeting intermediate standard, carry out capsule filling.
The preparation method of various compound recipe olanzapine fluoxetine hydrochloride capsules provided by the invention, the ratio that olanzapine mixes with pregelatinized Starch is mass ratio 1/20～1/1, wherein prioritizing selection 1/10.
The beneficial effect that technical solution of the present invention realizes:
Preparation method provided by the invention achieves producing compound recipe olanzapine fluoxetine hydrochloride capsules agent, take adjustment is produced the multiple means such as scheme and adjuvant, the dissolubility making active component olanzapine and fluoxetine Hydrochloride is dramatically increased than conventional technical scheme, be conducive to the performance of drug effect, related data is suitable with commercial like product, and entirety is better than commercial like product.
Detailed description of the invention
Technical scheme described in detail below.The embodiment of the present invention is only in order to illustrate technical scheme and unrestricted, although the present invention being described in detail with reference to preferred embodiment, it will be understood by those within the art that, the technical scheme of invention can be modified or equivalent replacement, without deviating from the spirit and scope of technical solution of the present invention, it all should be encompassed in scope of the presently claimed invention.
Embodiment 1.
Weigh recipe quantity olanzapine 60.46g respectively, fluoxetine Hydrochloride 279.6g, each three parts of pregelatinized Starch 1660.5g, three parts of recipe quantity olanzapine 60.46g are all mixed with the pregelatinized Starch 166.05g of 1/10 recipe quantity, mix with the fluoxetine Hydrochloride of 279.6g recipe quantity again, every part of remaining 1494.45g pregelatinized Starch finally adds mixed powder mix, cross 60 orders, 100 orders and 160 mesh sieves respectively, mix 20 minutes then through mixer, prepare into intermediate, detect its dissolution (referring to table 1).
Table 1
Embodiment 2
Weigh recipe quantity olanzapine 60.46g respectively, fluoxetine Hydrochloride 279.6g, each three parts of pregelatinized Starch 1660.5g, three parts of recipe quantity olanzapine 60.46g are mixed with pregelatinized Starch 83.03g, 166.05g, 1660.5g of 1/20,1/10 and 1 part of recipe quantity respectively, mix with the fluoxetine Hydrochloride of 279.6g recipe quantity again, finally every part of remaining 1577.47g, 1494.45g and 0g pregelatinized Starch are added mixed powder and mix, mixed powder is crossed 60 mesh sieves, mix 20 minutes then through mixer, prepare into intermediate, detect its dissolution (referring to table 2).
Table 2
Embodiment 3
Weigh recipe quantity olanzapine 60.46g respectively, fluoxetine Hydrochloride 279.6g, each three parts of pregelatinized Starch 1660.5g, the pregelatinized Starch 166.05g of first part of recipe quantity olanzapine 60.46g and 1/10 recipe quantity is mixed, mix with the fluoxetine Hydrochloride of 279.6g recipe quantity again, be eventually adding remaining 1494.45g pregelatinized Starch and mix；The fluoxetine Hydrochloride of second part of recipe quantity olanzapine 60.46g and 279.6g recipe quantity is mixed, then mixes with the pregelatinized Starch 166.05g of 1/10 recipe quantity, be eventually adding remaining 1494.45g pregelatinized Starch and mix；The pregelatinized Starch 166.05g of the fluoxetine Hydrochloride of the 3rd part of recipe quantity 279.6g recipe quantity and 1/10 recipe quantity is mixed, then mixes with recipe quantity olanzapine 60.46g, be eventually adding remaining 1494.45g pregelatinized Starch and mix；Mixed powder is crossed 60 mesh sieves, mixes 20 minutes then through mixer, prepare into intermediate, detection dissolution (referring to table 3).
Table 3
Embodiment 4
With reference to two annex XIXC crude drug of " Chinese Pharmacopoeia " version in 2010 and pharmaceutical preparation stability test guideline, we have carried out influence factor's experiment with same specification commercial samples at centering test agent specification 2 (olanzapine/fluoxetine is calculated as: 6mg/25mg), the results detailed in Table 4 and table 5.
Table 4 olanzapine fluoxetine hydrochloride capsules influence factor's result of the test (specification 2)
Table 5 olanzapine fluoxetine hydrochloride capsules influence factor's result of the test (commercial samples)
From table 4 and table 5, the olanzapine fluoxetine Hydrochloride preparation that technical solution of the present invention is produced, related data is suitable with commercial like product, and entirety is better than commercial like product.
Claims (5)
1. the preparation method of a compound recipe olanzapine fluoxetine Hydrochloride, it is characterized in that weighing recipe quantity olanzapine, fluoxetine Hydrochloride and pregelatinized Starch and carry out blended mixture, mixture is sieved more than 60 orders, mixes then through mixer, obtain compound recipe olanzapine fluoxetine Hydrochloride.
2. the preparation method of a compound recipe olanzapine fluoxetine Hydrochloride, it is characterized in that weighing recipe quantity olanzapine mixes with the pregelatinized Starch of part recipe quantity, mix with the fluoxetine Hydrochloride of recipe quantity again, the pregelatinized Starch being eventually adding remaining recipe quantity mixes, then the screening more than 60 orders, mix then through mixer, obtain compound recipe olanzapine fluoxetine Hydrochloride.
3. the preparation method of compound recipe olanzapine fluoxetine Hydrochloride according to claim 1 and 2, it is characterised in that the ratio that described olanzapine mixes with described pregelatinized Starch is mass ratio 1/20～1/1.
4. the preparation method of compound recipe olanzapine fluoxetine Hydrochloride according to claim 1 and 2, it is characterised in that the ratio that described olanzapine mixes with described pregelatinized Starch is mass ratio 1/10.
5. the preparation method of a compound recipe olanzapine fluoxetine hydrochloride capsules, it is characterised in that the compound recipe olanzapine fluoxetine Hydrochloride that the preparation method of the compound recipe olanzapine fluoxetine Hydrochloride described in claim 1 or 2 prepares is carried out capsule filling, prepares capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410823058.6A CN105769875A (en) | 2014-12-22 | 2014-12-22 | Preparation method of compound olanzapine fluoxetine hydrochloride capsule |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410823058.6A CN105769875A (en) | 2014-12-22 | 2014-12-22 | Preparation method of compound olanzapine fluoxetine hydrochloride capsule |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105769875A true CN105769875A (en) | 2016-07-20 |
Family
ID=56388727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410823058.6A Pending CN105769875A (en) | 2014-12-22 | 2014-12-22 | Preparation method of compound olanzapine fluoxetine hydrochloride capsule |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105769875A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084778A (en) * | 2019-12-31 | 2020-05-01 | 北京鑫开元医药科技有限公司 | A kind of olanzapine and fluoxetine hydrochloride capsule and preparation method thereof |
| CN112741819A (en) * | 2020-12-11 | 2021-05-04 | 山西仟源医药集团股份有限公司 | Fluoxetine hydrochloride capsule and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311681A (en) * | 1998-05-22 | 2001-09-05 | 伊莱利利公司 | combination therepy for treatment of refractory depression |
| CN101987090A (en) * | 2009-08-07 | 2011-03-23 | 上海秀新臣邦医药科技有限公司 | Fluoxetine capsule and preparation method thereof |
| CN102440974A (en) * | 2011-12-27 | 2012-05-09 | 天津市嵩锐医药科技有限公司 | Olanzapine orally disintegrating pharmaceutical composition |
-
2014
- 2014-12-22 CN CN201410823058.6A patent/CN105769875A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1311681A (en) * | 1998-05-22 | 2001-09-05 | 伊莱利利公司 | combination therepy for treatment of refractory depression |
| CN101987090A (en) * | 2009-08-07 | 2011-03-23 | 上海秀新臣邦医药科技有限公司 | Fluoxetine capsule and preparation method thereof |
| CN102440974A (en) * | 2011-12-27 | 2012-05-09 | 天津市嵩锐医药科技有限公司 | Olanzapine orally disintegrating pharmaceutical composition |
Non-Patent Citations (1)
| Title |
|---|
| FDA: "SYMBYAX", 《FDA APPROVED DRUG PRODUCTS》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084778A (en) * | 2019-12-31 | 2020-05-01 | 北京鑫开元医药科技有限公司 | A kind of olanzapine and fluoxetine hydrochloride capsule and preparation method thereof |
| CN112741819A (en) * | 2020-12-11 | 2021-05-04 | 山西仟源医药集团股份有限公司 | Fluoxetine hydrochloride capsule and preparation method thereof |
| CN112741819B (en) * | 2020-12-11 | 2022-07-22 | 山西仟源医药集团股份有限公司 | Fluoxetine hydrochloride capsule and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104039319B (en) | For treating HCV composition and method | |
| CN103655539B (en) | A kind of oral solid formulation of canagliflozin and preparation method thereof | |
| TW200418457A (en) | Oral solid form pharmaceutical and pharmaceutical for the treatment of dysuria | |
| EP2683245B1 (en) | Methods and compositions for treating depression using cyclobenzaprine | |
| CN102274227A (en) | Application of tetrandrine in preparation of drug for prevention and/or treatment of depression | |
| CN103191141B (en) | Application of 3-methoxyl mangiferin in preparing medicine used for treating post-stroke depression | |
| CN105213346A (en) | A kind of pharmaceutical composition containing cinacalcet hydrochloride and preparation method thereof | |
| CN106924210A (en) | A kind of capsule containing Pabuk former times profit cloth and preparation method thereof | |
| CN106265581B (en) | Tranexamic acid tablet and preparation method thereof | |
| CN104586806A (en) | Levetiracetam sustained release tablet as well as preparation method thereof | |
| CN106560179B (en) | Carilazine hydrochloride pharmaceutical composition and preparation method thereof | |
| CN103520725A (en) | Medicinal composition for treating emesis | |
| CN106309388A (en) | Medicine composition for treating congestive heart failure and preparation method thereof | |
| CN103893138B (en) | A kind of tablet containing linezolid form III | |
| CN101991561B (en) | 3,4-dichlorophenyl-propenoyl-sec-butylamine composition | |
| CN105769875A (en) | Preparation method of compound olanzapine fluoxetine hydrochloride capsule | |
| CN104940160B (en) | Improved Oseltamivir phosphate solid composite and preparation method thereof | |
| Lin et al. | Analysis of clinical trials of new drugs in China as of 2019 | |
| CN104523628B (en) | It is a kind of can direct powder compression butanedioic acid Solifenacin tablet and preparation method thereof | |
| CN107080741A (en) | Pirfenidone sustained release preparation and preparation method | |
| CN103520131B (en) | The preparation method of paroxetine hydrochloride semihydrate capsule | |
| CN106937947A (en) | Fluoxetine HCl capsules and preparation method thereof | |
| CN102429905B (en) | A pharmaceutical composition containing tetrahydropalmatine and imperatorin | |
| CN103463082A (en) | Telmisartan-amlodipine double-layer tablet and preparation method thereof | |
| CN106880606A (en) | A kind of proxetine hydrochloride tablets agent and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160720 |
|
| WD01 | Invention patent application deemed withdrawn after publication |